Trial
NCT04088760
TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
—
Condition
Allogeneic Hematopoietic Cell Transplantation
Intervention
TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)
Why stopped
Post-transplant cyclophosphamide and abatacept can be used as standard-of-care approaches to GVHD prevention in the HLA mismatched donor-recipient setting and are simpler to use since study enrollment is not required.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-08